Literature DB >> 33108102

RAAS Inhibitors and Risk of Covid-19.

Fabio Angeli1, Paolo Verdecchia2, Gianpaolo Reboldi3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33108102     DOI： 10.1056/NEJMc2030446

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients.

Authors:  Shilong Li; Rangaprasad Sarangarajan; Tomi Jun; Yu-Han Kao; Zichen Wang; Ke Hao; Emilio Schadt; Michael A Kiebish; Elder Granger; Niven R Narain; Rong Chen; Eric E Schadt; Li Li
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

Review 2.  Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis.

Authors:  Fabio Angeli; Gianpaolo Reboldi; Monica Trapasso; Gabriella Santilli; Martina Zappa; Paolo Verdecchia
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-09

Review 3.  Sequelae and Comorbidities of COVID-19 Manifestations on the Cardiac and the Vascular Systems.

Authors:  Yashvardhan Batta; Cody King; John Johnson; Natasha Haddad; Myriam Boueri; Georges Haddad
Journal:  Front Physiol       Date:  2022-01-14       Impact factor: 4.566

4.  Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry.

Authors:  Fabio Angeli; Paolo Verdecchia; Antonella Balestrino; Claudio Bruschi; Piero Ceriana; Luca Chiovato; Laura Adelaide Dalla Vecchia; Francesco Fanfulla; Maria Teresa La Rovere; Francesca Perego; Simonetta Scalvini; Antonio Spanevello; Egidio Traversi; Dina Visca; Michele Vitacca; Tiziana Bachetti
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.